Avidity’s del-zota elicits 25% increase in dystrophin in DMD patients
Avidity Biosciences’ Phase I/II trial of ribonucleic acid (RNA) therapy, del-zota, has increased dystrophin in patients with Duchenne muscular dystrophy …
Post
-
-
FDA removes hold on vTv’s cadisegliatin clinical programme for diabetes
The US Food and Drug Administration (FDA) has removed the clinical hold on vTv Therapeutics' cadisegliatin clinical programme, including the …
-
Orca Bio makes a splash as T-cell therapy cuts GvHD in blood cancer patients
Orca Bio’s T-cell immunotherapy candidate for blood cancers has more than doubled the number of patients surviving free of moderate-to-severe …
-
The future of eClinical technology interoperability: Have your say
Today’s clinical landscape is increasingly data-driven, and technology interoperability is critical for advancing research and improving outcomes. But what demands …
-
AstraZeneca’s $1bn hypoparathyroidism drug achieves success at Phase III
UK-based AstraZeneca’s acquired rare disease drug has met the primary endpoint in a Phase III trial in patients with chronic …
-
SolasCure initiates Phase II trial of chronic wound treatment gel
UK biotechnology company SolasCure has commenced the randomised, controlled CLEANVLU2 Phase II trial of Aurase Wound Gel for chronic wound …
-
Enrolment concludes in Zealand’s Phase IIb obesity therapy trial
Zealand Pharma has concluded enrolment for its global, randomised Phase IIb ZUPREME-1 trial, assessing the long-acting amylin analogue, petrelintide, in …
-
Measles outbreak in the US largest since 2019
The United States is experiencing a multi-state measles outbreak, resulting in the highest case spike since 2019. There are currently …
-
Incyte stock hit 11% despite paediatric dermatology trials hitting target
Incyte’s stock price has taken a hit of more than 11%, despite two Phase III trials investigating its oral small-molecule …
-
Anocca gains European authorisation for Phase I/II trial of pancreatic cancer drug
Swedish immunotherapy company Anocca has secured authorisation from regulatory authorities in four European nations for its Phase I/II VIDAR-1 clinical …
-
Clinical trial challenges in China: How a Sharp and ClinsChain pairing is breaking down barriers
The market for clinical trials in China is currently experiencing significant growth, driven by increasing activity from both Chinese sponsors …
-
Dyne’s DMD trial advances patient mobility and dystrophin expression
Patients with Duchenne muscular dystrophy (DMD) have seen an “unprecedented and sustained” functional improvement in a Phase I/II trial examining …
-
Scholar Rock SMA drug shows muscle function benefit
Scholar Rock’s spinal muscular atrophy (SMA) therapy has shown benefit in muscle function in children under 12 in a pivotal …
-
World Tuberculosis Day 2025: the end of TB is possible
The international community will celebrate World Tuberculosis Day on Monday, 24 March this year. The theme for 2025 is “Yes! …
-
Palisade Bio begins dosing subjects in last cohort of ulcerative colitis drug trial
US-based biopharmaceutical company Palisade Bio has begun dosing subjects in the last cohort of its Phase Ia/b trial of PALI-2108 …
